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LETTERS TO THE EDITOR
Abnormal Cellularity in
Asymptomatic Relatives of Patients
With Idiopathic Dilated Cardiomyopathy
I read with great interest the study by Mahon et al. (1) demon-
strating abnormal myocardial pathology in apparently asymptom-
atic relatives of patients with idiopathic dilated cardiomyopathy
(DCM). This finding, of course, has great clinical import. The
investigators state that their study “provides, for the first time, to
the best of our knowledge, direct pathologic confirmation that
relatives with LVE (left ventricular enlargement) have myocardial
disease . . .”. Several years ago, histopathologic changes were re-
ported in a smaller number of asymptomatic first-degree relatives
of patients with DCM (2). That study claimed, more correctly, to
have shown “for the first time that the myocardium in such
relatives demonstrates abnormal cellularity”. The study was pub-
lished in a nonobscure, English-language journal and, most su-
prisingly, Dr. Mahon was one of the co-authors!
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REPLY
The study to which Dr. McKenna refers (1), focusing principally on
the evaluation of two markers of apoptosis and a single, unquantified
marker of inflammation, was considered to be hypothesis-generating
but by no means confirmatory. It was recognized to have been limited
not only by an incomplete and insensitive evaluation of myocardial
inflammation, but more importantly by very small numbers (n  5)
and the lack of a control group. Accordingly, the investigators
themselves quite deliberately and correctly concluded that “the obser-
vations described must be viewed as provocative but preliminary.”
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Efficacy of Biventricular
Pacing in Congestive Heart Failure
Linde et al. (1) reported in the Journal that biventricular pacing
significantly improves clinical parameters in patients with conges-
tive heart failure. In their study, the 6-min walking distance, New
York Heart Association class, and quality of life improved with
biventricular pacing. Objective measures of function, including the
maximal O2 consumption, left ventricular end-diastolic diameter, left
ventricular end-systolic diameter, and left ventricular ejection fraction
did not improve significantly. The investigators were only able to
demonstrate subjective improvement but not any objective improve-
ment with the biventricular pacing. Subjective improvement was
previously shown by Linde et al. (2) to improve with sham pacing,
suggesting that a significant placebo effect is associated with the
insertion of a pacemaker. It is therefore possible that the subjective
improvement in this group was a result of the placebo effect of
pacemaker implantation rather than of the mode of pacing utilized.
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In their letter, Moshenyat and colleagues suggest that the one-year
benefits by biventricular pacing in the MUSTIC trial reflect the
placebo effect by pacemaker implantation because no significant
one-year improvements in objective parameters were found (1). The
MUSTIC trial was designed as a randomized single-blind crossover
comparison between biventricular pacing and inactive pacing (sinus
rhythm) or right ventricular pacing (atrial fibrillation) assuming a 10%
improvement in 6-min walk and a 10% reduction in Minnesota score
by three months of active (biventricular) treatment (2). The crossover
results indicate a 20% improvement in 6-min walk and a 30%
improvement in quality of life. Subsequent long-term follow-up
indicates that these benefits were sustained in magnitude over a one-
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and two-year follow-up (1,3,4). Because sample size was not calcu-
lated for subsequent long-term follow-up no statistical calculations for
the secondary end points such as left ventricular dimensions in the
recently published one-year follow-up were made (1).
The placebo effect can be described as the sum of the treatment
effect and the true placebo. The placebo effect by pacemaker
implantation was described by us in 1999 in a study with similar
crossover design as the present and of patients paced for hyper-
trophic obstructive cardiomyopathy (5). Like in the MUSTIC
trial, long-term follow-up demonstrated a sustained beneficial
effect on both objective and subjective parameters (4,5). The
placebo effect has been shown to fade by time, rarely lasting more
than six months. For the MUSTIC study, sustained two-year
benefits by biventricular pacing in both groups of patients (6,7)
have been reported. Therefore, we strongly believe that the
observations found in the present study reflect the treatment effect
induced by biventricular pacing rather than the placebo effect.
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